EGFR and neoplasm: This suggests that not only the presence of mutated but also the expression levels of wild-type K-ras are important for tumor progression and may serve as predictive marker for therapy efficacy, especially when occurring in combination with other genetic alterations such as EGFR mutations or ERBB2 amplifications.